Page 2 - Simon Travis News Today

Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.“Idiopathic inflammation of the pouch — referred to as pouchitis — is the most common long-term complication of ileal pouch-anal anastomosis (IPAA); it

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

The medication also showed favorable endoscopic and histologic responses.

12% of people with ulcerative colitis need surgery to have their colon removed (colectomy). Most of those have an ileo-anal pouch surgically constructed from their small bowel, which means that they don't have to live with a stoma bag.

FRIDAY, March 31, 2023 (HealthDay News) -- For patients with chronic pouchitis after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis, treatment with vedolizumab is more effective

For patients with chronic pouchitis after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis, treatment with vedolizumab is more effective than placebo for inducing remission.

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus... | March 30, 2023

Biologic effective for common complication of ileal pouch-anal anastomosis in ulcerative colitis

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that...